PAF receives additional funding support for serving patients with multiple myeloma

Nov 13 2009

Co-Pay Relief Program Provides Direct Financial Support for Pharmaceutical Co-Payments to Insured Patients in Medical and Financial Need

Patient Advocate Foundation (PAF) -- a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases -- is pleased to announce that it has received additional funding support for serving patients with multiple myeloma through its Co-Pay Relief Program (CPR).

PAF's Co-Pay Relief Program provides direct financial support for pharmaceutical co-payments to insured patients, including Medicare Part D beneficiaries, who financially and medically qualify. Since the program's inception in April 2004, CPR distributed more than $50 million in assistance to over 25,000 patients who were unable to afford their pharmaceutical co-payments.

"Patient Advocate Foundation is committed to improving the quality of life of patients facing medical and financial hardship through our professional case management and Co-Pay Relief services. We are thrilled to announce additional funding for our Co-Pay Relief Program, which will allow us to offer financial assistance to a larger number of Multiple Myeloma patients across the nation," said Nancy Davenport-Ennis, Founder and CEO of PAF. "A cancer diagnosis can be the most overwhelming experience a person may ever face in his or her lifetime. Coupled with high-cost pharmaceutical co-pay expenses, the journey can become significantly more challenging to manage -- so we are particularly pleased to be able to offer assistance to more patients."

"We are so pleased that the Patient Advocate Foundation was able to secure this additional funding for Multiple Myeloma patients. Through PAF's Co-Pay Relief Program, this funding will help Multiple Myeloma patients to better utilize their healthcare coverage, which will lead to more thorough management of their disease," said Anne Quinn Young, MPH, Director of Programs, Multiple Myeloma Research Foundation.

Multiple myeloma is a cancer of the plasma cell, an important part of the immune system that produces antibodies to help fight infection and disease.

SOURCE Patient Advocate Foundation